Hints and tips:
...Shares in Pfizer added about 1 per cent on Friday, while Seagen was up about 0.9 per cent....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...There was a March release date given for Gran Turismo 7 and the unfortunate slippage of Grand Theft Auto V from November to March. Axios has more....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Lentz joins from Thompson & Knight. Latham & Watkins has hired Meghan Cocci as a partner in the law firm’s corporate department....
...Directed by Zack Synder, 2016 Warner Bros The themes come thick and fast — the morality of power, democracy — but Batman v Superman skids across the surface, leaving characters and notions underdeveloped...
...The battle ended with Allergan securing a huge premium from “white knight” bidder Actavis, the generics pharma company, which paid $70.5bn to buy the company in a deal that closed in March....
...Some investors even say such a deal could pave the way for Mr Saunders to eventually replace Ian Read as chief executive of Pfizer....
...Their bid was derailed by Actavis, which bought Allergan for $66bn after emerging as a “white knight” bidder and sealing the biggest M&A deal of 2014....
...With the ink barely dry on his employment contract, he proposed taking over Allergan, which was in a bitter fight against a takeover by Valeant and hedge fund Pershing Square, and in search of a white knight...
...move marks a return to big-ticket deal making for Mike Pearson, Valeant’s chief executive, after his hostile attempt to buy Allergan last year was thwarted when Actavis emerged with a rival $66bn “white knight...
...This week, Allergan confirmed it had been approached by a rival bidder, understood to be Actavis, in a sign that it could seek a white knight to help it deter Valeant’s advances....
...Talks with Actavis, a potential “white knight”, had been bubbling away in the background but gathered new momentum as the December meeting got closer....
...The chief executive of GlaxoSmithKline all but ruled out a white knight bid by the UK pharmaceuticals company for AstraZeneca on Wednesday by reiterating scepticism on big takeover deals in the sector....
...Pfizer are engaging with us because they value life sciences.” GlaxoSmithKline on Wednesday indicated it would not be tempted to mount a “white knight” bid to combine the UK’s two biggest drugmakers....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Sanofi is among those touted by analysts as a potential “white knight,” but Chris Viehbacher, chief executive, this week said he was not looking to do a big deal....
...Knight Capital remained weak. The key broker in US equities, which was hit by a software glitch, fell 2.1 per cent to $2.84....
...Drugmaker Pfizer added 2.1 per cent to $23.62, while Merck rose 0.8 per cent to $44.17, its highest level in more than four years....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...forced Sanofi-Aventis to sweeten its original cash offer, adding to an initial purchase price that already represented a high multiple to current earnings, and which had failed to solicit any rival “white knight...
...Oliver Brandicourt of the drug group’s primary care unit, Ruth McKernan, head of Pfizer’s Sandwich site, Rod MacKenzie of worldwide research and Pfizer UK managing director Richard Blackburn faced the grilling...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
International Edition